| Outcome Measures: |
Primary: Area under the plasma concentration versus time curve (AUC) of gemigliptin, dapagliflozin, empagliflozin, AUCτ, day1, day6, day7 0, 0.5, 1,1.5,2,2.5,3,4,5,6,8,12,16,24 hours|Peak Plasma Concentration (Cmax) of gemigliptin, dapagliflozin, empagliflozin, Css,max, day1, day6, day7 0, 0.5, 1,1.5,2,2.5,3,4,5,6,8,12,16,24 hours | Secondary: tss,max of gemigliptin, dapagliflozin, empagliflozin, tss,max, day1, day6, day7 0, 0.5, 1,1.5,2,2.5,3,4,5,6,8,12,16,24 hours|minimum blood plasma concentration of gemigliptin, dapagliflozin, empagliflozin, Css,min, day1, day6, day7 0, 0.5, 1,1.5,2,2.5,3,4,5,6,8,12,16,24 hours|Area under the plasma concentration versus time curve (AUC) of gemigliptin metabolite, AUCτ, day1,day6,day7 0, 0.5, 1,1.5,2,2.5,3,4,5,6,8,12,16,24 hours|Peak Plasma Concentration (Cmax)of gemigliptin metabolite, Css,max, day1,day6,day7 0, 0.5, 1,1.5,2,2.5,3,4,5,6,8,12,16,24 hours|minimum blood plasma concentration(Css,min) of gemigliptin metabolite, Css,min, day1,day6,day7 0, 0.5, 1,1.5,2,2.5,3,4,5,6,8,12,16,24 hours|metabolic ratio of gemigliptin, metabolic ratio, day1,day6,day7 0, 0.5, 1,1.5,2,2.5,3,4,5,6,8,12,16,24 hours
|
